BlossomHill Therapeutics and Latigo Biotherapeutics both reached the Nasdaq Global Select Market with proceeds above their original IPO targets. The pair add to a 2026 biotech class that BioSpace said is already the largest since 2021 once their offerings are counted.
BlossomHill Therapeutics and Latigo Biotherapeutics both reached the Nasdaq Global Select Market with proceeds above their original IPO targets. The pair add to a 2026 biotech class that BioSpace said is already the largest since 2021 once their offerings are counted.
READ MORE
Denali Therapeutics reported $3.6 million in first-quarter-on-market revenue for Avlayah, ahead of analyst expectations after the Hunter syndrome drug was approved on March 25 and launched in April. The company also raised third quarter revenue guidance to $10 million to $12 million.
Clinical readouts, a large pharma deal and recent policy moves have pushed psychedelics closer to a real commercial test in psychiatry. The remaining question is less whether the drugs can work than whether sponsors can scale them into routine care.
Sanofi told patient groups and physicians in the U.S. and Europe that supplies of Myozyme and Nexviazyme are dwindling. The shortages emerged shortly after the Food and Drug Administration warned the company over manufacturing issues at its Irish facility.
Replimune is shifting from a prolonged regulatory fight to a measured commercial launch after the FDA approved Tudriqev for advanced melanoma. The company is betting that broad labeling and physician demand can support uptake in a market with limited options after anti-PD-1 treatment failure.
Braveheart Bio is set to debut on Nasdaq with an upsized IPO expected to raise $382.5 million. The offering adds to a broader rebound in biotech listings after a market that was largely shut for most of 2025.
A Stanford-led study found that tau may drive neurodegeneration by disrupting mitochondrial electron flow, creating reactive oxygen species, cellular stress and inflammation. The work suggests a new way to intervene beyond simply targeting tau aggregates.
The Trump administration said it is starting the process to decertify Kentucky-based organ procurement organization Network for Hope over what it called persistent safety failures. The move puts operational safeguards in organ donation under sharper federal scrutiny at a time when more than 100,000 people remain on the transplant list.
Workplace violence in healthcare settings remains a persistent challenge, with incidents often occurring despite the presence of scattered risk data. Experts argue that the true gap lies in the integration and visibility of risk indicators—an issue hospitals and systems must address to enhance prevention.
The NIH’s move to block international students on visas from the K99 Pathways to Independence program ignites discussion over the future of biomedical research careers and U.S. science leadership.
Beyond cavity prevention and gum health, dental care experts are looking at how the bite—jaw alignment and muscular function—shapes long-term oral wellness.
